Adagio Medical restructures to focus on US pivotal IDE trial; reduces workforce

Adagio Medical Holdings, Inc.

Pauses limited European launch of vCLAS catheter; redirects resources to US FULCRUM-VT Pivotal IDE trial (over 35% enrolled).
Reduction in force effective February 28, 2025, to enable additional investment in clinical trial and product design optimization.
Streamlining operations and realigning resources toward US FDA premarket approval for VT Cryoablation System with vCLAS catheter.
CEO Todd Usen cites broad applicability of ultra-low temperature cryoablation technology and aim to lead ventricular tachycardia market.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.